Unilife ($UNIS) - All articles and blogs now @ ProActive Newsroom

 Email Article  

Tweet  

  

  

  

 delicious  

  

Unilife Corp (UNIS) - "50 Companies to Watch" and S-1 Registration

 Email Article  

Tweet  

  

  

  

 delicious  

  

Unilife Corporation (UNIS) was recently included in the Medical Device and Diagnostic Industry (MDDI) magazine’s annual “50 Companies to Watch” list.

MDDI compiles the list with solicited nominations from its Editorial Advisory Board and other sources, which are then analyzed to identify “companies that have achieved success and manufacturers with the potential to revolutionize care practices. All are companies that are making an outstanding contribution to healthcare and that are expected to continue doing so." MDDI is a leading source of in-depth news and information for original equipment manufacturers of medical devices.

UNIS - S-1 resale registration statement with the United States Securities and Exchange Commission

Once declared effective by the SEC, the registration statement will remove restrictions which apply to the sale of shares issued to optionholders on exercise of their options. This will allow optionholders to freely trade those shares (other than affiliates of Unilife to which certain re-sale restrictions will still apply). The options to which this registration statement applies are the replacement Unilife Corporation options which were issued to optionholders upon the redomiciliation undertaken by the Unilife Group in January 2010.

The Company has filed this registration statement because under U.S. securities laws, the underlying shares issued, should these options be exercised, would be considered to be privately placed shares which could not be resold without a registration statement.

The Company will update optionholders upon the registration statement being declared effective.

Unilife Corp (UNIS) Appoints R. Richard Wieland II to CFO

 Email Article  

Tweet  

  

  

  

 delicious  

  

Unilife brings in a new CFO to catch the growth:

"Mr. Wieland, 65, has over 30 years of senior financial experience with U.S.-based public and private companies. He has served as the CFO of four NASDAQ-listed companies within the life sciences industry, and as a senior executive of two New York Stock Exchange-listed companies.

Most recently, Mr. Wieland served as the CFO of Cytochroma Inc., a privately-held specialty pharmaceutical company. From 2004 to 2008, Mr. Wieland served as Executive Vice-President and CFO of Advanced Life Sciences Holdings, Inc., a NASDAQ-listed clinical-stage biopharmaceutical company. Prior to that, Mr. Wieland served as a senior executive of other NASDAQ-listed life science and healthcare companies, including Option Care, Inc., where he was a Board member, President and Chief Operating Offer."

 Full Press Release 

Unilife Corporation (Nasdaq: $UNIS) - Third Quarter Fiscal 2010 (3/31/10) Earnings #ProActiveNR

 Email Article  

Tweet  

  

  

  

 delicious  

  

I posted my notes from last week's UNIS call with the management of Unilife at the following websites:

Seeking Alpha - Mike Sweeney on UNIS

My research website - OIR

Med Students' Needle-Handling Error Exposes Patients to Potential Infection #ProActiveNR $UNIS

 Email Article  

Tweet  

  

  

  

 delicious  

  

Sent to me by a Unilife investor:

The Associated Press is reporting that a group of medical students at the University of New Mexico School of Medicine in Albuquerque did not properly change out needles on medical devices used to test blood glucose levels, thus putting as many as 50 patients at risk for contracting bloodborne pathogens.

The University of New Mexico School of Medicine has posted the following announcement on its Web site:

“On Saturday, April 24, 2010, a group of students from the University of New Mexico Physician Assistant program were volunteering at the Indian Pueblo Cultural Center in Albuquerque during the Center’s American Indian Week “Pueblo Days” to offer free voluntary blood sugar tests. The device used to prick the finger to get the blood sample required for testing was meant for single patient use and not for multiple patients. Those who volunteered for testing that day may have been put at risk of contracting infections due to potential exposure to diseases spread by blood contact. “Despite direct faculty supervision, three mistakes were made: They used the wrong device; they were not all properly trained on the device; no records of those tested were kept.

“We estimate that 51 to 55 individuals were tested, potentially exposing these people to other's blood. The diseases of greatest concern are hepatitis B and C although theoretically HIV is also possible. Our best current assessment of the risk of infection is less than a 0.5 percent risk. Even though the risk is small it is something we are very concerned about it and are taking it seriously.

“UNM School of Medicine deeply regrets this error and wants to apologize to all those who may have been exposed, and to the Indian Pueblo Cultural Center. We are asking that those who were tested come forward so we can better assess any risk from this episode and assure that exposed persons receive appropriate follow-up testing and care. If you know someone who was tested please contact us.

“Those who may have been exposed will be offered follow-up testing for Hepatitis B, C, and HIV. The costs of testing will be covered by UNM.

“Public health authorities are requesting that those who participated in the diabetes screening event should contact 1-888-899-6092 for more information and referral for screening. You may also use this web form to make contact.”
 

Unilife Corporation Schedules Third Quarter Fiscal 2010 Conference Call For Thursday, May 13, 2010

 Email Article  

Tweet  

  

  

  

 delicious  

  

Unilife Corporation (NASDAQ: UNIS; ASX; UNS) - Enters the India market

 Email Article  

Tweet  

  

  

  

 delicious  

  

"Dr. Gerald Verollet, Vice-President of Scientific and International Affairs, has relocated to India to co-ordinate discussions between Unilife and government agencies, healthcare facilities and pharmaceutical companies regarding the use of Unilife's proprietary range of safety syringes. Prior to joining Unilife in 2003, Dr. Verollet was the head of Medical Devices at the World Health Organization (WHO), playing a key role in the development and adoption of international standards for Auto-Disable (AD) syringes that incorporate safety features to automatically prevent the reuse and sharing of syringes.

Unilife has also appointed Clinicare, a Mumbai-based national leader in the supply of innovative safety medical devices to Indian healthcare facilities and pharmaceutical companies, as its exclusive local partner. In addition to supporting Unilife's business development activities within India, Clinicare will also act as the Company's authorized national representative to secure the registration of its Unitract™ 1mL syringes with local regulatory authorities."

Unilife (NASDAQ: UNIS) Featured Cover Story on Pharmaceutical and Medical Packaging News

 Email Article  

Tweet  

  

  

  

 delicious  

  

Unilife Cover Picture

Unilife (NASDAQ: UNIS) had a very nice April 2010 cover story in the their trade magazine Pharmaceutical and Medical Packaging News: 

Unilife features syringe safety technology integrated into the barrel of the syringe. After the dose is administered, a retraction mechanism automatically engages. The healthcare worker can then control the rate of needle extraction without removing the needle from the injection site. The technology is used in Unilife’s Unifill ready-to-fill syringe, and in the 1-ml Unitract disposable plastic syringe.
 
Unilife’s integrated safety system’s functional and automatic safety features allow retraction of the needle directly from the body, reducing the risk of needle exposure compared with conventional clip-on safety devices. These require the user to remove the needle from the injection site to operate the safety mechanism thus exposing the needle. Clinicians are reported to remove the needle from the patient before activating the needle retraction, which is rapid and uncontrolled, Shortall says.
 
“[Using the Unifill and Unitract syringes], the operator is in control of the process because they control the rate of retraction as the needle retracts directly from the patient,” he says.
 
Unilife and sanofi-aventis announced an agreement last month in which sanofi-aventis will have five-year exclusive rights to negotiate the purchase of the Unifill ready-to-fill syringe in therapeutic classes including antithrombotic agents and vaccines.

Full Cover Story

Crystal Research Associates issues report in Unilife (NASDAQ: UNIS)

 Email Article  

Tweet  

  

  

  

 delicious  

  

Unilife (NASDAQ: UNIS) $2.2M loan via Governor Ed Rendell of Pennsylvania

 Email Article  

Tweet  

  

  

  

 delicious  

  

With its $2.2 million loan - approved Thursday by the state's Commonwealth Financing Authority - Unilife will bring 241 new jobs in York County and retain its current 87 employees, according to a press release from the state's Department of Community Economic Development. The new jobs will range from engineering and automated assembly to quality control and testing.

Rendell said the $2.2 million the state is investing in Unilife also will serve as crucial gap financing to help it finish building a $27 million corporate headquarters and manufacturing facility.

"Unilife made a commitment to Pennsylvania when it decided to move its global headquarters from Australia," Rendell said in a statement. "We're keeping our commitment by providing financial resources that will ensure this vital project is completed."

Full article